HIMS: Bull Flag detected on 21 Jul 2026

HIMS is forming a bull flag pattern following a strong run driven by Q1 2026 earnings momentum and the Novo Nordisk partnership. The pattern exhibits excellent structure (15.0/15) and solid volume characteristics (12.0/12), though the breakout score of 9.8/13 indicates moderately firm confirmation. At $32.70, the stock sits between support at $31.91 and resistance at $39.05, with the 73.21% win probability suggesting this is a technically sound setup in a bullish sector regime (0.55).

Q1 2026 results showed demand surging across core offerings, with the Novo Nordisk partnership cited as a key driver of raised full-year guidance. Management raised 2026 revenue guidance to $2.8b–$3b and reiterated 2030 targets of $6.5b revenue and $1.3b adjusted EBITDA, though results showed an adjusted loss per share of $0.18 and pressure on gross margins. Investors are increasingly focused on the growing peptides business and GLP-1 weight loss drugs as long-term growth drivers. Analyst sentiment is mixed, with 4 Buy, 8 Hold, and 0 Sell ratings from 12 analysts over the past 3 months, with price targets ranging from $21 to $40. Institutional activity remains mixed, with 230 institutional investors adding shares while 370 decreased positions in the most recent quarter.

A successful bull flag breakout would target above $39.05 resistance, with analyst conversations citing targets reaching $40 and higher. The conservative target sits at $33.78, implying a modest 3.3% measured move from current levels. Historical technical setups have tracked the stock climbing over 60% in a month, though the current pattern suggests a more restrained immediate move. The pattern invalidates below the $31.91 support level. At 73.21% win probability, this setup aligns with the sector's bullish regime, indicating above-average odds for upside continuation.

Recent weakness—down 4.89% in one week and 14.58% in two weeks—suggests momentum waning despite bullish long-term fundamentals. Valuation metrics raise concerns despite recent strength, leading to mixed investor sentiment. Gross margin pressure and near-term earnings challenges persist as the company shifts toward higher-value categories, creating near-term profitability headwinds. Q1 2026 results missed on EPS (–$0.19 vs. +$0.13 est.) by 244%, though revenue nearly met expectations. The beta of 2.09 signals elevated volatility relative to the broader market. Volume ratio of 0.59 is below average, limiting conviction in near-term breakout momentum.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.